Tous Actualités
Suivre
Abonner Antisoma plc

Antisoma plc

Antisoma Acquires Cytogen's Royalty Rights To R1549

London, UK and Princeton, New Jersey USA (ots)

Antisoma plc
(LSE: ASM; Nasdaq Europe: ASOM), a United Kingdom-based
biopharmaceutical company, and Cytogen Corporation (Nasdaq: CYTO), a
United States-based, product-driven, oncology-focused
biopharmaceutical company, today announced that Antisoma has acquired
certain royalty rights to Antisoma's lead product, R1549 (formerly
Pemtumomab), from Cytogen.
In connection with Antisoma's acquisition of such rights, Antisoma
made a cash payment to Cytogen of USD $500,000, and has agreed to
make an additional payment of USD $500,000 upon the first commercial
sale, if any, of its R1549 product. In return, Cytogen relinquished
its right to receive royalties equivalent to 1.65% of net sales
revenues, if any, of Antisoma's R1549 product.  Cytogen was entitled
to such royalties pursuant to its grant of a licence to certain
technology, upon which R1549 is based, to Antisoma and Imperial
Cancer Research Technology Limited (now Cancer Research Technology
Ltd).
R1549 is being co-developed by Antisoma and Roche.  Roche has
worldwide marketing rights under an agreement between the companies
signed in November 2002. R1549 is expected to complete a pivotal
phase III study in ovarian cancer between December 2003 and February
2004, and the major findings of the trial are expected to be released
during the first half of 2004.
Michael D. Becker, President and Chief Executive Officer of
Cytogen Corporation, stated, "We believe that our transfer of royalty
rights relating to R1549 to Antisoma will benefit both Cytogen and
Antisoma.  We expect to utilize the additional working capital to
further enhance our focused business plan, primarily by continuing to
develop our sales and marketing efforts for Quadramet®, for which
we recently reacquired marketing rights in August 2003 from Berlex
Laboratories, Inc."
Commenting on the transaction, Glyn Edwards, CEO of Antisoma,
said, "This will increase our net income from future sales of R1549,
and adds to the potential upside for our shareholders as we await the
results from the pivotal study."
About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. Antisoma fills
its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions.  Its core activity is the pre-clinical and
clinical development of these drug candidates. Antisoma forms
partnerships with pharmaceutical companies to bring its products to
market. In November 2002, Antisoma signed a ground-breaking
collaboration agreement with Roche to develop and commercialise
products from Antisoma's pipeline. For more information about
Antisoma, visit the website at www.antisoma.com
Antisoma Disclaimer
Except for the historical information presented, certain matters
discussed in this statement are forward looking statements that are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from results, performance or
achievements expressed or implied by such statements. These risks and
uncertainties may be associated with product discovery and
development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and
regulatory filings. Such statements are based on management's current
expectations, but actual results may differ materially.
About Cytogen
Cytogen Corporation of Princeton, NJ is a product-driven,
oncology-focused biopharmaceutical company. Cytogen markets
proprietary and licensed oncology products through its in-house
specialty sales force: Quadramet® (a skeletal targeting therapeutic
radiopharmaceutical for the relief of pain due to bone metastases);
ProstaScint® (a monoclonal antibody-based imaging agent used to
image the extent and spread of prostate cancer); and NMP22®
BladderChek™ (a point-of-care, in vitro diagnostic test for bladder
cancer). Cytogen has exclusive U.S. marketing rights to Combidex®,
an ultrasmall superparamagnetic iron oxide contrast agent for
magnetic resonance imaging of lymph nodes that is pending clearance
by the U.S. Food and Drug Administration. Cytogen's pipeline
comprises product candidates at various stages of clinical
development, including fully human monoclonal antibodies and cancer
vaccines based on PSMA (prostate specific membrane antigen)
technology, which was exclusively licensed from Memorial
Sloan-Kettering Cancer Center. Cytogen also conducts research in
cellular signaling through its AxCell Biosciences research division
in Newtown, PA. For more information, please visit the Company's
website at www.cytogen.com, which is not part of this press release.
ProstaScint® is a registered United States trademark of Cytogen
Corporation. All other trade names, trademarks or service marks
appearing in this press release are the property of their respective
owners, and not the property of Cytogen or any of our subsidiaries.
Quadramet® is a trademark of The Dow Chemical Company used under
license by Cytogen.
Cytogen Disclaimer
This press release contains certain "forward-looking" statements
within the meaning of the Private Securities Litigation Reform Act of
1995 and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements, other than statements of historical facts,
included in this press release regarding our strategy, future
operations, financial position, future revenues, projected costs,
prospects, plans and objectives of management are forward-looking
statements.
The words "anticipates," "believes," "estimates," "expects," 
"intends," "may," "plans," "projects," "will," "would" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Such forward-looking statements involve a number of risks and
uncertainties and investors are cautioned not to put any undue
reliance on any forward-looking statement. There are a number of
important factors that could cause Cytogen's results to differ
materially from those indicated by such forward-looking statements.
Such factors are discussed in Cytogen's Form 10-K for the year ended
December 31, 2002, as amended, and from time-to-time in Cytogen's
other filings with the Securities and Exchange Commission. Any
forward-looking statements made by Cytogen do not reflect the
potential impact of any future acquisitions, mergers, dispositions,
joint ventures or investments Cytogen may make. Cytogen does not
assume, and specifically disclaims, any obligation to update any
forward-looking statements, and these statements represent Cytogen's
current outlook only as of the date given.
This information is provided by RNS
   The company news service from the London Stock Exchange

Contact:

Antisoma plc:
Glyn Edwards,
Chief Executive Officer
Tel. +44/20/8799-8200

Financial Dynamics:
Jonathan Birt
Tel. +44/207/269-7187

Cytogen Corporation:
Michael D. Becker,
Chief Executive Officer
Tel, +1/(609)/750-8289

Plus de actualités: Antisoma plc
Plus de actualités: Antisoma plc
  • 22.08.2003 – 08:17

    Results Presented From As1403 Phase I Biodistribution Study

    London, UK plc (LSE:ASM, NASD-E:ASOM) (ots) - Antisoma announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be presented this weekend to the European Association of Nuclear Medicine meeting in Amsterdam by Dr Michael Garkavij, a leading investigator in the trial. AS1403 is a fragment of the monoclonal antibody HMFG1 linked to a radioactive isotope with cell-killing ...